ANDREW GALE

Summary

Affiliation: The Scripps Research Institute
Country: USA

Publications

  1. pmc Continuing education course #2: current understanding of hemostasis
    Andrew J Gale
    Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, CA 92037, USA
    Toxicol Pathol 39:273-80. 2011
  2. ncbi request reprint Molecular characterization of an extended binding site for coagulation factor Va in the positive exosite of activated protein C
    Andrew J Gale
    Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, California 92037, USA
    J Biol Chem 277:28836-40. 2002
  3. ncbi request reprint An engineered interdomain disulfide bond stabilizes human blood coagulation factor VIIIa
    A J Gale
    Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, CA 92037, USA
    J Thromb Haemost 1:1966-71. 2003
  4. ncbi request reprint Intrinsic stability and functional properties of disulfide bond-stabilized coagulation factor VIIIa variants
    A J Gale
    Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, CA 92037, USA
    J Thromb Haemost 4:1315-22. 2006
  5. ncbi request reprint Characterization of a factor Xa binding site on factor Va near the Arg-506 activated protein C cleavage site
    Andrew J Gale
    Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, CA 92037, USA
    J Biol Chem 282:21848-55. 2007
  6. doi request reprint Cathepsin G, a leukocyte protease, activates coagulation factor VIII
    Andrew J Gale
    Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, California 92037, USA
    Thromb Haemost 99:44-51. 2008
  7. pmc Detailed mechanisms of the inactivation of factor VIIIa by activated protein C in the presence of its cofactors, protein S and factor V
    Andrew J Gale
    Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, California 92037, USA
    J Biol Chem 283:16355-62. 2008
  8. pmc Engineered virus-like nanoparticles reverse heparin anticoagulation more consistently than protamine in plasma from heparin-treated patients
    Andrew J Gale
    Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, CA 92037, USA
    Thromb Res 128:e9-13. 2011
  9. doi request reprint The anticoagulant function of coagulation factor V
    Thomas J Cramer
    Department of Molecular and Experimental Medicine, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA
    Thromb Haemost 107:15-21. 2012
  10. ncbi request reprint Factor Va residues 311-325 represent an activated protein C binding region
    Subramanian Yegneswaran
    Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, California 92037, USA
    J Biol Chem 282:28353-61. 2007

Research Grants

Detail Information

Publications14

  1. pmc Continuing education course #2: current understanding of hemostasis
    Andrew J Gale
    Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, CA 92037, USA
    Toxicol Pathol 39:273-80. 2011
    ..Thus, improved understanding of hemostasis continues to lead to benefits for patients...
  2. ncbi request reprint Molecular characterization of an extended binding site for coagulation factor Va in the positive exosite of activated protein C
    Andrew J Gale
    Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, California 92037, USA
    J Biol Chem 277:28836-40. 2002
    ..In conjunction with previously published work, these results define an extensive FVa binding site in the positive exosite of APC that is primarily involved in binding and cleaving at Arg(506) on FVa...
  3. ncbi request reprint An engineered interdomain disulfide bond stabilizes human blood coagulation factor VIIIa
    A J Gale
    Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, CA 92037, USA
    J Thromb Haemost 1:1966-71. 2003
    ..This remarkably stable C664-C1826 FVIIIa provides a unique approach for studies of the cofactor activity of FVIIIa and also for new, improved therapy for hemophilia A...
  4. ncbi request reprint Intrinsic stability and functional properties of disulfide bond-stabilized coagulation factor VIIIa variants
    A J Gale
    Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, CA 92037, USA
    J Thromb Haemost 4:1315-22. 2006
    ..This engineered disulfide bond resulted in a more stable FVIIIa...
  5. ncbi request reprint Characterization of a factor Xa binding site on factor Va near the Arg-506 activated protein C cleavage site
    Andrew J Gale
    Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, CA 92037, USA
    J Biol Chem 282:21848-55. 2007
    ....
  6. doi request reprint Cathepsin G, a leukocyte protease, activates coagulation factor VIII
    Andrew J Gale
    Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, California 92037, USA
    Thromb Haemost 99:44-51. 2008
    ..Therefore, it is possible that cathepsin G from neutrophils and monocytes may provide some pro-coagulant effect by activating FVIII...
  7. pmc Detailed mechanisms of the inactivation of factor VIIIa by activated protein C in the presence of its cofactors, protein S and factor V
    Andrew J Gale
    Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, California 92037, USA
    J Biol Chem 283:16355-62. 2008
    ..As a result, in the presence of both activated protein C cofactors, Arg(336) cleavage is only twice as fast as Arg(562) cleavage. Therefore, both cleavages contribute significantly to factor VIIIa inactivation...
  8. pmc Engineered virus-like nanoparticles reverse heparin anticoagulation more consistently than protamine in plasma from heparin-treated patients
    Andrew J Gale
    Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, CA 92037, USA
    Thromb Res 128:e9-13. 2011
    ..These results provide the first step towards validation of heparin antagonist VLPs as viable alternatives to protamine...
  9. doi request reprint The anticoagulant function of coagulation factor V
    Thomas J Cramer
    Department of Molecular and Experimental Medicine, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA
    Thromb Haemost 107:15-21. 2012
    ..6) The prothrombotic function of FV(Leiden) is a function of both reduced APC cofactor activity and resistance of FVa to APC inactivation. However, detailed structural and mechanistic properties remain to be further explored...
  10. ncbi request reprint Factor Va residues 311-325 represent an activated protein C binding region
    Subramanian Yegneswaran
    Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, California 92037, USA
    J Biol Chem 282:28353-61. 2007
    ..These data suggest that peptide VP311-325 represents both an APC and fXa binding region in fVa...
  11. pmc Prothrombin amino terminal region helps protect coagulation factor Va from proteolytic inactivation by activated protein C
    Subramanian Yegneswaran
    Department of Molecular and Experimental Medicine, The Scripps Research Institute, 10550, North Torrey Pines Road, MEM180, La Jolla, CA, 92037, USA
    Thromb Haemost 101:55-61. 2009
    ..Only following FII activation and dissociation of the FII Gla domain fragments from the FII-ase complex, can APC inactivate FVa and down-regulate thrombin generation...
  12. pmc Interdomain engineered disulfide bond permitting elucidation of mechanisms of inactivation of coagulation factor Va by activated protein C
    Andrew J Gale
    Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, California 92037, USA
    Protein Sci 11:2091-101. 2002
    ..Nonetheless, for FVa Leiden (Gln506-FVa) inactivation by APC, A2 domain dissociation may become mechanistically important, depending on the ambient FXa concentration...
  13. ncbi request reprint Characterization of a thrombomodulin binding site on protein C and its comparison to an activated protein C binding site for factor Va
    Andrew J Gale
    Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, California 92037, USA
    Proteins 54:433-41. 2004
    ..Thus, the extensive basic surface of protein C and activated protein C provides distinctly different, though significantly overlapping, binding sites for recognition by thrombin-thrombomodulin and factor Va...
  14. ncbi request reprint Activated protein C variants with normal cytoprotective but reduced anticoagulant activity
    Laurent O Mosnier
    Department of Molecular and Experimental Medicine MEM 180, The Scripps Research Institute, 10550 N Torrey Pines Road, La Jolla, CA 92037, USA
    Blood 104:1740-4. 2004
    ..We suggest that therapeutic use of such APC variants may reduce serious bleeding risks while providing the beneficial effects of APC acting directly on cells...

Research Grants1

  1. Stabilized factor VIIIa as improved therapy for hemophilia A
    ANDREW GALE; Fiscal Year: 2008
    ..This treatment could improve the quality of life and overall health of the hemophilia A sufferers. ..